{"id":"comparator-placebo-to-sitagliptin","safety":{"commonSideEffects":[{"rate":"7-8","effect":"Nasopharyngitis"},{"rate":"5-6","effect":"Headache"},{"rate":"4-5","effect":"Upper respiratory tract infection"},{"rate":"1-2","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sitagliptin is a DPP-4 inhibitor that prevents the degradation of GLP-1 and GIP, incretin hormones that regulate postprandial glucose levels. By extending the half-life of these hormones, sitagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby lowering blood glucose in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning it primarily acts when blood glucose is elevated, reducing hypoglycemia risk.","oneSentence":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:13.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01928199","phase":"PHASE4","title":"Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-09","conditions":"Posttransplant Diabetes Mellitus","enrollment":61},{"nctId":"NCT04161430","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01-02","conditions":"Type 2 Diabetes Mellitus","enrollment":766},{"nctId":"NCT04982705","phase":"PHASE1","title":"IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2021-07-07","conditions":"Type 2 Diabetes","enrollment":94},{"nctId":"NCT02683187","phase":"PHASE1","title":"DPP4 Inhibition & Beta Cell Function","status":"COMPLETED","sponsor":"David D'Alessio, M.D.","startDate":"2017-03-01","conditions":"Healthy","enrollment":40},{"nctId":"NCT03359590","phase":"PHASE2","title":"Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2018-03-21","conditions":"Pharmacological Action","enrollment":20},{"nctId":"NCT03646721","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2018-08-29","conditions":"Diabetes Mellitus, Type 2","enrollment":108},{"nctId":"NCT02377388","phase":"PHASE3","title":"DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-02-07","conditions":"Platelet Aggregation During Acute Myocardial Infarction","enrollment":74},{"nctId":"NCT01991197","phase":"PHASE2","title":"Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2014-04","conditions":"Psoriasis, Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02647320","phase":"PHASE2","title":"12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":298},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01462266","phase":"PHASE3","title":"Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-01-13","conditions":"Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT00888238","phase":"PHASE1","title":"A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-05-12","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT00976261","phase":"PHASE1","title":"A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-17","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00837577","phase":"PHASE3","title":"MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":133},{"nctId":"NCT00830076","phase":"PHASE1","title":"A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT00704132","phase":"PHASE1","title":"Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-14","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":57},{"nctId":"NCT00813995","phase":"PHASE3","title":"A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-09","conditions":"Type 2 Diabetes Mellitus","enrollment":395},{"nctId":"NCT00730275","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-18","conditions":"Type 2 Diabetes","enrollment":35},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00511108","phase":"PHASE1","title":"Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07-11","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":211},{"nctId":"NCT00397631","phase":"PHASE3","title":"Initial Combination With Pioglitazone Study (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-19","conditions":"Type 2 Diabetes Mellitus","enrollment":520},{"nctId":"NCT00395343","phase":"PHASE3","title":"Sitagliptin Added-on to Insulin Study (0431-051)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-11","conditions":"Type 2 Diabetes Mellitus","enrollment":641},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00305604","phase":"PHASE3","title":"Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03-08","conditions":"Type 2 Diabetes","enrollment":206},{"nctId":"NCT00103857","phase":"PHASE3","title":"MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03-17","conditions":"Type 2 Diabetes Mellitus","enrollment":1208},{"nctId":"NCT02015910","phase":"PHASE4","title":"Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2014-01","conditions":"Type II Diabetes","enrollment":1},{"nctId":"NCT00631488","phase":"PHASE2","title":"A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":146},{"nctId":"NCT00337610","phase":"PHASE3","title":"Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":190},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT01413542","phase":"NA","title":"Pharmacogenetics of Ace Inhibitor-Associated Angioedema","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2011-11","conditions":"Hypertension, Diabetes Type 2","enrollment":44},{"nctId":"NCT00541775","phase":"PHASE3","title":"Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus","enrollment":273},{"nctId":"NCT00975052","phase":"PHASE1","title":"A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT00289848","phase":"PHASE3","title":"MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03","conditions":"Type 2 Diabetes Mellitus","enrollment":530},{"nctId":"NCT01035879","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-12","conditions":"Diabetes","enrollment":100},{"nctId":"NCT01824264","phase":"PHASE2","title":"Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284},{"nctId":"NCT00684528","phase":"PHASE3","title":"A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2008-06","conditions":"Diabetes Type 2","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":367,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: placebo to sitagliptin","genericName":"Comparator: placebo to sitagliptin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}